Janus Global Life Sciences Fund (JAGLX)
Sector Experts Seeking Growth and Innovation in Health Care



Inception Date12/31/1998
NAV (As of 4/27/15 )$60.88
Total Net Assets (As of 3/31/15)$4.31B
Annual Expense Ratio
(As of fiscal year end 9/30/14)
GROSS 0.93%
NET 0.93%

Performance (As of 3/31/15)
1 Year42.40%
3 Year37.04%
5 Year26.97%
10 Year15.75%
Morningstar (As of 3/31/15)
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

120 Funds Rated
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Straight Talk

Chapter 1 (1 of 3)

Health Care Investing

Portfolio Manager Andy Acker explains why rapid innovation and changing demographics make health care investing attractive

Chapter 2 (2 of 3)

Team & Approach

Andy Acker discusses what opportunities he’s seeing in the health care sector

Chapter 3 (3 of 3)

Understanding the Science and the Business

Meet some of the members of the Janus Health Care team and learn how they approach analyzing this complex sector.

Quarterly Commentary - Q1 2015


Quarterly returns in health care outpaced those of the broader market and were driven by a surge in merger and acquisition activity, especially among biotechnology names.

Biotechnology companies drove Fund performance,while health care technology stocks detracted most from relative results.

Pharmacyclics led contributors, followed by Valeant Pharmaceuticals and Biogen Idec.

We expect the wave of innovative therapies aimed at the highest, unmet medical needs to continue into the foreseeable future.


Andy Acker, CFA

Fund Manager since 2007
Industry since 1996